Grifols S.A. ADR (GRFS)

$GRFS Grifols paid a higher price to buy blood plasma from an entity linked to its controlling family than from third-party suppliers, according to a regulator’s findings submitted in a court case ….

$GRFS Grifols pagó hasta un 39% más para comprar plasma a Scranton Según las conclusiones de un regulador presentadas en un caso judicial, la farmacéutica española también acordó pagar a Scranton un margen fijo del 16,5% sobre los costes Bad news

$GRFS bad news ? Weird day

JP Morgan updates rating for Grifols ( $GRFS ) to Neutral, target set at 7.6 → 10.3.

$GRFS U.S. court rules to go on with Grifol lawsuit against Gotham City, Reuters says A New York court has found enough evidence to continue with the defamation lawsuit filed by Grifols against short seller Gotham City Research, Reuters reports. The Federal District Court for the Southern District of New York rejected Gotham City's request to dismiss the lawsuit, but did narrow it by rejecting some claims.

After a strong start, is $ADMA still the best bet, or is $GRFS taking the lead? 🏆 💡 ADMA boasts robust Asceniv demand and 15.9% gains in 2025, but trades at a pricey 25.48X forward earnings. 📈 Meanwhile, GRFS, with its wider portfolio and Zacks Rank #2 (Buy), offers a cheaper 7.19X valuation and a significant EPS improvement of 296% in 2025. Discover which stock could be your next winner 👉 https://www.zacks.com/commentary/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-body&ADID=SYND_STOCKTWITS_TWEET_2_2478303_BODY

At current levels, $GRFS scores over $ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum. Explore further: https://www.zacks.com/stock/news/2478303/adma-biologics-vs-grifols-which-plasma-therapy-stock-is-the-better-buy?cid=sm-stocktwits-2-2478303-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2478303_TEASER

Fresh Upgrades and Downgrades After-Hours! $CR $INGN $GRFS $MU $SWK and more in play! Analysts reshuffled the deck - who's your pick going into Friday? stocksrunner.com/news/2025-05-22-thursday-analyst-upgrades-and-downgrades

$GRFS bad candle last session

$GRFS Just initiated a position. They have a "2029 plan" to reduce the debt. Promising.

$GRFS take over soon

$GRFS 🤫🤩 Holly s... check this out... I remember what they've did last time, it's a retail war against hedge funds... I'm in. BUY BUY BUY 🥳🤛🧨🚀🚀🚀

$GRFS $JSPR take over .. this is the end of

$GRFS over SMA.

$GRFS $JSPR …

$JSPR $GRFS next to takeover (opa) soon Under real value from months

$GRFS Grifols clarifies no knowledge of restarted discussion on offer from Brookfield Pursuant to the provisions of Article 227 of Law 6/2023 of March 17, on Securities Markets and Investment Services, Grifols, S.A. hereby informs about the following: With respect to information published in certain media outlet regarding discussions having restarted with respect to a potential new offer for Grifols' shares from Brookfield Capital Partners Limited, the Company informs that its Board of Directors has no knowledge regarding this information.

Brookfield has restarted talks with the Grifols family $GRFS over a potential offer for the Spanish blood-plasma firm, after walking away from a deal last year. No formal bid yet, but discussions are back on.

$KOMP $KSPI $GRFS $HSAI https://wallstreetwaves.com/exploring-komps-core-assets-for-a-26-profit-opportunity/

$GRFS Grifols Loses Over 5% After Securities Market Commission Report Slams POSTED BY: THE CORNER 10TH MARCH 2025 CdM | Grifols shares lost more than 5% on the stock market on Monday. Last Friday, after the market had closed, a report was published by the National Securities Market Commission (CNMV) that was highly critical of the company’s financial management…

$GRFS bad moment…here …out

$GRFS Grifols responds to 'misleading media report' Grifols issued a statement to address certain information published in a media outlet on March 8, specifically a front-page article titled "The CNMV reveals to the judge 'continuous fraud' among the top executives of Grifols", which also continues today. "Neither the article nor its title reflect the reality. The article addresses certain statements made in the Legality Opinion from the CNMV's legal service, which was used to support the decision of the CNMV's Executive Committee on 25 September 2024 to initiate administrative sanctioning proceedings against Grifols, S.A. and its Directors. The proceedings concern allegations of including inaccurate data or omitting significant information in the consolidated annual financial reports and management report for 2021 to 2023 and the half-year financial information for 2023. The resolution mentioned above is primarily the act of initiating an administrative sanctioning procedure that can last up to one year and its purpose is to determine whether any potential infringements it addresses have occurred. Grifols, S.A. and the affected Directors, have the right to present their allegations and evidence-a right they have both exercised. However, the news article fails to mention the following important details: The Executive Committee which reflects the CNMV's position, when adopting the initiation agreement, publicly communicated it to the market on the same date. In this communication, the CNMV explicitly stated that the alleged deficiencies which prompted the proceedings 'did not result in material inaccuracies in the regulated accounting figures' and that 'Grifols basic accounting figures were not incorrect (except for the accounting treatment of two specific transactions [....] which have been explained and separately restated by the company in the first half of 2024'; Both the Legality Opinion referenced in the news item and the resolution from the Executive Committee, when analysing the conduct of Grifols, S.A. and its Directors, clearly rule out any fraud (dolo) explicitly stating that: 'As for the subjective title under which the infringement is attributed, it must be considered in both infringements as being of a culpable or negligent nature, since the facts do not reveal a predetermined and voluntary action aimed at achieving an illicit purpose nor contravening the rule'. Additionally, the Executive Committee highlights that the alleged irregularities did not result in any financial gain," the company stated.